• Paul K Drain, Kristina L Bajema, David Dowdy, Keertan Dheda, Kogieleum Naidoo, Samuel G Schumacher, Shuyi Ma, Erin Meermeier, David M Lewinsohn, and David R Sherman.
• Department of Global Health, University of Washington, Seattle, Washington, USA pkdrain@uw.edu.
• Clin. Microbiol. Rev. 2018 Oct 1; 31 (4).

AbstractTuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding of its clinical pathogenic spectrum of infection and disease. Historically, scientific research, diagnostic testing, and drug treatment have focused on addressing one of two disease states: latent TB infection or active TB disease. Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses. This revised understanding leads us to propose two additional clinical states: incipient and subclinical TB. The recognition of incipient and subclinical TB, which helps divide latent and active TB along the clinical disease spectrum, provides opportunities for the development of diagnostic and therapeutic interventions to prevent progression to active TB disease and transmission of TB bacilli. In this report, we review the current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium.Copyright © 2018 American Society for Microbiology.

15 keywords...

hide…